The aerospace market is being disrupted by electrification, creating opportunities for new types of aircraft, improved economics, and lower emissions
Verdego Aero: Leading the Electrification of the $1.2T Aerospace Industry
BACKGROUND ON COMPANY
Revolutionary cell therapy targeting a cure for both Type 1 and Type 2 diabetes
Successful demonstration of curative properties in animal models, with a human clinical trial targeted for 2021
Utilization of ethically derived human induced pluripotent stem cells (iPSC, non-embryonic), which have the potential for significant scaleup to reach greater patient populations while avoiding ethical concerns
RMS has been highly successful in obtaining significant non-dilutive capital from sources such as the NIH in order to supplement existing family office investors including Ratan Tata
RMS’ patented stem cell technology is built on over 20 years of research and unique scientific expertise
COVID-19 has demonstrated that diabetics are at significant risk for serious complications and death with the coronavirus, highlighting that diabetes puts significant parts of the population at risk
WHAT YOU WILL LEARN FROM THIS WEBINAR
Diabetes affects an estimated 463 million people worldwide and will rise to 700 million by 2040 without intervention, thus illustrating the urgent need for a therapeutic solution from RMS
Diabetes and its complications are costing the world healthcare system an estimated $825 billion annually
Learn how RMS’ technology can significantly reduce the great financial burden globally
Every 6 seconds a person dies from diabetes and continues to be one of the world’s fastest growing diseases
RMS’ therapeutic grade cells are directly analogous to the successful cadaveric islets procedure (insulin independence), but without the supply limitations, variability, high cost and inconsistencies of cadaver islets
Investments in companies that treat/monitor diabetes have produced extraordinary results…imagine the potential investment returns of a company that can cure diabetes
